An advisory panel convened by the U.S. Food and Drug Administration last week voted to allow compounding pharmacies to manufacture the peptides epitalon and semax, while narrowly voting against permitting the compounding of emideltide. The votes followed the panel’s earlier decision to recommend permitting four other peptides to be compounded by pharmacies.
The panel’s latest recommendations move federal policy closer to making multiple unapproved peptides available through compounding pharmacies. Those developments align with a stated objective of U.S. Health and Human Services secretary Robert F. Kennedy Jr., who has advocated increasing access to these compounds.
The FDA advisory committee’s decisions could reshape availability of several peptides that are not approved through the standard drug-approval pathway. Peptides have gained attention and demand in the United States in recent years, a rise attributed in part to endorsements by social media influencers.
Compounding pharmacies operate under a different regulatory framework than manufacturers of approved drugs. A recommendation from an FDA advisory panel does not itself change law or agency rules, but such votes can influence future FDA enforcement priorities and policy decisions about how unapproved products are handled in practice.
The source reporting did not provide the complete vote tallies for each peptide, the panel’s rationale for the emideltide decision beyond the narrow vote characterization, nor the specific conditions or limitations the panel might have suggested for compounding these products. Those details were not included in the publicly available excerpt.
Separately, Amgen has submitted new evidence to the FDA and is seeking a hearing to challenge the agency’s April proposal to withdraw Tavneos from the U.S. market.
The FDA’s April proposal cited a lack of proven effectiveness for Tavneos and alleged false statements in the drug’s original marketing application. Tavneos is used to treat a rare autoimmune disease that damages blood vessels.
Amgen disputes the agency’s conclusions. In its filing seeking a hearing, the company said it included more than 70 real-world studies encompassing over 2,200 patients intended to support Tavneos’ effectiveness and safety. The company has framed the submission as new evidence that warrants a formal review and a hearing to contest the proposed withdrawal.
When the FDA proposes to withdraw an approved drug, the agency typically details its basis for doing so, often pointing to failures to demonstrate efficacy in post‑approval data or to problems with the original approval. A company can then request a hearing and submit additional data or arguments in defense of the product. The public excerpt did not include the FDA’s full rationale, the contents of Amgen’s submission beyond the number of studies and patients, or a timetable for when a hearing might occur.
Both stories—the peptide compounding votes and the Tavneos dispute—touch on wider tensions in contemporary drug regulation.
The peptide votes reflect pressure to expand access to unapproved compounds through compounding pharmacies, a move that can raise questions about quality control, oversight, and the balance between patient demand and evidence standards. The panel’s split decisions suggest regulators are grappling with differing risk‑benefit profiles across individual peptides.
The Amgen–FDA clash over Tavneos highlights another dynamic: how regulators and drugmakers handle disputed evidence after initial approval. Amgen’s submission of real-world studies signals an attempt to use observational data to bolster a drug’s profile when the agency raises concerns about effectiveness.
Both scenarios underscore that evidence standards and the interpretation of real-world data remain central to regulatory decisions and to disputes between manufacturers and the FDA.
On the peptide front, the FDA advisory panel’s recommendations are an influential step but not a final regulatory action. Any change in how compounding pharmacies may produce these peptides will depend on subsequent steps by the FDA and possibly by other federal or state regulators.
For Tavneos, Amgen’s filing asking for a hearing initiates a formal process in which the company and the FDA will present arguments and evidence. The source did not report a schedule for a hearing or further procedural milestones following Amgen’s submission.
This item is drawn from public reporting summarized in the source excerpt. Some parts of the original STAT piece were behind the outlet’s STAT+ subscription service; the publicly available text did not include the full story or additional details that may be present in the subscriber content.
If you want deeper coverage, the original reporting from STAT and Reuters cited in the source may provide fuller vote counts, the panel’s deliberations, and the specific documentation Amgen submitted to the FDA, but those items were not reproduced in the excerpt used for this summary.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.